Common questions about BREVITAL (FAQ)
Q: What is the main reason doctors use BREVITAL?
Official documents state that BREVITAL is primarily used for the intravenous induction of anesthesia. It can also be used as part of a combined anesthetic approach for short or long surgical, diagnostic, or therapeutic procedures to help induce a hypnotic state.
Q: Is BREVITAL used for things other than its primary indication?
The official product information indicates that it has multiple approved uses beyond induction of anesthesia. These include its use as a supplemental agent within combined anesthesia for various surgical, diagnostic, or therapeutic procedures.
Q: What is the expected length of time BREVITAL's effects usually last?
BREVITAL is classified as an ultrashort-acting barbiturate, meaning its effects are designed to be brief, leading to a rapid recovery. According to clinical pharmacology information, the half-life of the drug in the body is approximately 1.6 hours.
Q: How does BREVITAL differ from other similar medicines that treat the same condition?
BREVITAL is chemically distinct from certain older barbiturate anesthetics because it does not contain sulfur. Clinical pharmacology data also indicates that its duration of action is significantly shorter—about half as long as drugs like thiamylal and thiopental.
Q: Can BREVITAL cause long-term side effects?
Regulatory warnings, based on animal studies, address the potential for long-term effects. These documents suggest that repeated or prolonged use of the drug (longer than 3 hours) in children under 3 years old may lead to long-term cognitive or behavioral changes.
Q: Is it common to feel confused or groggy after receiving BREVITAL?
Reported adverse reactions include confusion and drowsiness (grogginess) that can occur as patients emerge from anesthesia. Feelings of anxiety or restlessness may also occur in some patients.
Q: What are the most commonly reported side effects of BREVITAL?
According to official documents, commonly reported effects include nausea, vomiting, stomach pain, drowsiness, and confusion. Other effects that may occur are muscle twitching, chills, shivering, coughing, hiccups, and itching.
Q: Are there any specific foods or drinks that should be avoided while BREVITAL is in the system?
The official drug information explicitly states that the drug's central nervous system (CNS) depressant effects are enhanced when combined with ethyl alcohol. No specific warnings regarding foods are included in the regulatory warnings for this drug.
Q: Does BREVITAL interact with common pain relief medications?
The CNS depressant effects of BREVITAL are known to be additive with narcotics and opioids. Official product information notes that caution is advised when the drug is administered with any agent that may increase central nervous system depression.
Q: Can people with liver or kidney issues use BREVITAL?
Regulatory warnings suggest that caution should be exercised for patients who have hepatic (liver) or renal (kidney) impairment, as the hypnotic effect of the drug may be prolonged in these cases. Official documents note that severe liver dysfunction may lead to the selection of a different agent entirely.
Q: Is BREVITAL considered a controlled substance?
BREVITAL (methohexital sodium) is classified as a Schedule IV controlled substance under the Controlled Substances Act. This classification indicates a recognized potential for abuse and dependence, though it is lower than some other schedules.
Q: What is the significance of the black box warning on BREVITAL's label?
The product labeling includes a warning regarding the potential for negative effects on the developing brain, based on animal studies. This warning applies to children younger than 3 years old when the drug is used repeatedly or for periods longer than 3 hours.
Q: Why is BREVITAL only administered in a hospital or clinical setting?
Regulatory documents specify that the drug should be administered only in settings that provide for continuous monitoring of respiratory and cardiac function, with resuscitative equipment readily available. This practice is required due to the potential risk of serious breathing issues, including respiratory depression and cardiorespiratory arrest.
Q: What happens in the body once the effect of BREVITAL wears off?
The rapid effect of the drug wears off mainly because it quickly redistributes from the brain to other body tissues. Official clinical pharmacology information states that the drug is then broken down (metabolized) primarily in the liver through processes like demethylation and oxidation.
Q: Is BREVITAL safe for use in pediatric patients (children)?
The drug is officially indicated for use in pediatric patients older than one month. However, a specific warning exists about prolonged use (longer than 3 hours) in children younger than 3 years old due to potential effects on brain development, based on animal studies.
Q: Are there any published research papers on the safety of BREVITAL during pregnancy?
Regulatory documents state that use during pregnancy is recommended only when the potential benefit to the mother clearly justifies the potential risk to the fetus. It is known to rapidly cross the placenta, and no controlled human studies on pregnant women are available.
Q: Does using BREVITAL carry a risk of dependence or addiction?
The drug is classified as a Schedule IV controlled substance. This classification indicates that while there is a recognized potential for abuse, the risk of physical or psychological dependence is noted as being limited compared to substances in higher schedules.
Q: Is BREVITAL the same drug as pentothal?
No, BREVITAL (methohexital) is chemically different from certain older barbiturate anesthetics and has a shorter duration of action. For example, its effect is only about half as long as that of the drug thiopental, which is related to Pentothal.
Q: What medical conditions would prevent someone from being able to use BREVITAL?
The drug is contraindicated in patients with a known allergy or hypersensitivity to barbiturates. It is also restricted for use in patients who have latent or manifest porphyria, a specific genetic enzyme disorder.
Q: How does BREVITAL affect the ability to drive or operate machinery afterward?
Official product information advises that individuals should avoid operating machinery or driving a motor vehicle for 8 to 12 hours after awakening from anesthesia. This restriction is due to the potential for residual drowsiness and impaired thinking.
Q: Do people typically experience nausea or vomiting after receiving BREVITAL?
Nausea and vomiting are reported adverse reactions. Official documents state that the incidence of these effects is low when the drug is administered to patients who have been fasting.
Q: Does BREVITAL affect heart rate or blood pressure?
The induction of anesthesia may cause transient hypotension (a temporary drop in blood pressure) and tachycardia (a fast heart rate). Circulatory depression and cardiovascular instability are listed as potential serious risks.
Q: How long after using BREVITAL is it considered safe to breastfeed?
Available data suggests that a waiting period is typically not required before resuming breastfeeding after receiving a single dose. This is because the amounts excreted into milk are considered very small.
Q: What evidence is available regarding BREVITAL's use in emergency situations?
The official indications state that the drug is used for procedures requiring rapid, ultrashort-acting anesthesia. However, the regulatory documentation for general use does not specifically define or limit the indications to only 'emergency' situations.
Q: Is BREVITAL available as a generic version?
The non-proprietary name, methohexital sodium, is available as a generic equivalent to the brand name Brevital Sodium.
Q: Why is BREVITAL sometimes used in combination with other medicines?
It is often used as a supplemental agent, or adjunct, alongside other subpotent inhalational anesthetics or other parenteral agents. This combined use is typically employed for surgical procedures that are longer than the drug's rapid effects.
Q: What does 'contraindication' mean in relation to BREVITAL?
A contraindication is a specific medical condition or circumstance that explicitly makes the use of the drug unsuitable. For BREVITAL, examples include a known allergy to barbiturates or the presence of latent or manifest porphyria.
Q: Is it true that certain genetic factors can change how a person reacts to BREVITAL?
Official contraindications list latent or manifest porphyria, which is a genetic enzyme disorder, as a specific reason to restrict the use of the drug. This disorder affects how the body processes certain medications, including barbiturates.
Q: What are the rules about using BREVITAL in elderly patients?
While no specific elderly-only dosing rules are provided, official information suggests that caution should be exercised in debilitated patients or those with impaired respiratory, circulatory, kidney, liver, or endocrine systems. These conditions are common in the elderly population.
Q: Do official prescribing documents mention anything about long-term effects on memory?
Official documents do contain a warning about the potential for long-term cognitive deficits based on animal studies. This warning applies when the drug is used repeatedly or for periods longer than 3 hours in the developing brains of children younger than 3 years old.
Q: Why is the drug given intravenously (into a vein)?
The drug is primarily given intravenously because this route allows for rapid uptake by the brain. This mechanism ensures the immediate onset of effect and the rapid induction of sleep, typically within 30 seconds.
Q: Can I experience an allergic reaction to BREVITAL?
A known allergy or hypersensitivity to barbiturates is listed as a contraindication for using the drug. Allergic reactions, including the serious reaction known as anaphylaxis, are noted as possible adverse reactions.
Q: How is BREVITAL typically stored before it is used?
The drug is supplied as an oxygen-sensitive powder. Regulatory documents state that once the powder is prepared into a solution, it should be freshly made and used promptly. The reconstituted solution is noted as being chemically stable at room temperature for up to 24 hours.
Q: Does the package insert for BREVITAL contain information on how it is eliminated from the body?
The clinical pharmacology information in the package insert confirms that the drug is broken down (metabolized) primarily in the liver through demethylation and oxidation. The final elimination occurs via the kidneys through glomerular filtration.
Q: What patient populations are explicitly warned against using BREVITAL?
Patients with porphyria or a known barbiturate hypersensitivity are officially contraindicated (restricted from use). Caution is also advised for those with severe dysfunction of the liver, kidneys, or cardiovascular system, as well as those with pulmonary disease or severe anemia.
Q: What is the risk of having a serious side effect from BREVITAL?
Official warnings highlight the potential for serious side effects, including cardiorespiratory arrest, respiratory depression (severe slowing of breathing), laryngospasm, and seizures. This is the basis for the requirement that the drug be administered in a highly monitored setting.
